Author: Ken Dropiewski

Possible Breakthrough in Cardiovascular Disease Diagnostics for the United States

Coronary/Structural Heart by 0 comments

SINGAPORE, Dec. 16, 2022 /PRNewswire/ — Neuome Peptides Pte. Ltd., a Singapore-based company has established an assay-development platform, powered by machine learning and novel, patented algorithms for the quantifiable detection of biomarkers. The company successfully designed specific peptides to bind to pre-established, proven biomarkers for Cardiovascular Diseases and is currently developing effective diagnostic assays. The use of small peptides, conjugated with gold nanoparticles, allows a […]

Continue Reading →

HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2023 Financial Results

Financial by 0 comments

Patient Enrollment Close to Completion and Continue to Target FDA De Novo Resubmission Around Current Fiscal Year End Southlake, Texas, Dec. 16, 2022 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also […]

Continue Reading →

ELECTRODUCER ANNOUNCES THE PUBLICATION OF POSITIVE RESULTS FROM ITS PILOT STUDY IN EUROINTERVENTION MEDICAL JOURNAL

Coronary/Structural Heart by 0 comments

The first of its kind study involved 60 patients and confirmed Electroducer Sleeve® as a safe and effective treatment for heart diseases The company plans to launch its device in the US market by the end of 2023, followed by the European market in 2024 Grenoble, France, December 15, 2022 – Electroducer, […]

Continue Reading →

BioCardia Announces $3.6 Million Private Placement of Common Stock

Financial by 0 comments

SUNNYVALE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a Securities Purchase and Registration Rights Agreement (the “Purchase Agreement”) relating to a private placement with […]

Continue Reading →

Aziyo Biologics Announces Funding of Additional $4 Million Term Loan with SWK Holdings Corporation

Financial by 0 comments

Follows recent equity financing, resulting in debt and equity gross proceeds of $15.2 million SILVER SPRING, Md., Dec. 15, 2022 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, […]

Continue Reading →

Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease

Rhythm by 0 comments

Companies initiate research agreement supporting development of new AI-ECG algorithm to help identify patients who may be at risk of cardiac amyloidosis CAMBRIDGE, Mass.–(BUSINESS WIRE)–Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has entered into a multi-year agreement with Pfizer, Inc. for Anumana to develop an artificial intelligence […]

Continue Reading →

Synchron Raises $75M Series C Led by ARCH Venture Partners to Advance Endovascular Brain-Computer Interface

Financial by 0 comments

Top-tier investor syndicate includes new investors ARCH Venture Partners, Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X, with follow on participation from existing investors including Khosla Ventures, NeuroTechnology Investors, METIS, Forepont Capital Partners, ID8 Investments, Shanda Group and University of Melbourne. […]

Continue Reading →

Johnson & Johnson Announces Extension of Abiomed Tender Offer to December 21, 2022

Financial by 0 comments

NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ), the world’s largest, most diversified healthcare products company, today announced that Athos Merger Sub, Inc. (“Offeror”), a wholly owned subsidiary of Johnson & Johnson, has extended the expiration date of its offer (the “Offer”) to acquire all of the outstanding shares of […]

Continue Reading →

Valo Health – FDA Collaborative Study in Human Cardiac Tissues Demonstrates Potential to Predict Clinical Efficacy of Cardiac Contractility Modulation Devices to Treat Heart Failure

Coronary/Structural Heart Regulatory by 0 comments

Findings Part of Five-Year Research Collaboration Between Valo and FDA Developed on Valo’s Biowire Platform BOSTON, Dec. 14, 2022 /PRNewswire/ — Valo Health, Inc (“Valo”) shared the initial results of a collaborative study with the U.S. Food and Drug Administration (FDA), demonstrating the potential of Valo’s Biowire platform to predict clinical efficacy of Cardiac […]

Continue Reading →
1 … 423 424 425 426 427 … 1,295